Retraction

SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide

Retraction Details

Nature of Retraction:

Retraction

Retraction Notice:
10.1038/s41375-024-02443-z
Additional Notes:

see also: https://pubpeer.com/publications/BE119832A5B1091025C04244B43F5D

Citations (213)

213
Total Citations
5
Post-Retraction
(2.3%)
208
Pre-Retraction
0
Same Day
Post-Retraction Citation Analysis
2 Within 30 days
5 Within 1 year
0 After 2+ years
204 Days since retraction (latest)
A new era of immune therapy in multiple myeloma
Yu‐Tzu Tai, Kenneth C. Anderson
Blood Open Access
Published: Jul 2016
17 citations
3015 days before retraction
Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication
Gang An, Chirag Acharya, Xiaoyan Feng et al. (10 authors)
Blood Open Access
Published: Jul 2016
158 citations
3021 days before retraction
Monoclonal antibodies for treating multiple myeloma - a new era, new safety considerations?
Stefania Oliva, Antonio Palumbo
Expert Opinion on Drug Safety Open Access
Published: Jun 2016
3 citations
3038 days before retraction
The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor–Mediated Cross-Linking
Marije B. Overdijk, J.H. Marco Jansen, Maaike Nederend et al. (8 authors)
The Journal of Immunology Open Access
Published: Jun 2016
258 citations
3048 days before retraction
Future therapeutic options for patients with Waldenström macroglobulinemia
Jorge J. Castillo, Zachary R. Hunter, Guang Yang et al. (6 authors)
Best Practice & Research Clinical Haematology
Published: Jun 2016
4 citations
3065 days before retraction
Novel therapeutic targets in Waldenstrom macroglobulinemia
Aneel Paulus, Sikander Ailawadhi, Asher Chanan‐Khan
Best Practice & Research Clinical Haematology
Published: Jun 2016
9 citations
3065 days before retraction
APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment
Yu‐Tzu Tai, Chirag Acharya, Gang An et al. (15 authors)
Blood Open Access
Published: Apr 2016
296 citations
3098 days before retraction
Emerging antibodies for the treatment of multiple myeloma
Flora Zagouri, Evangelos Terpos, Efstathios Kastritis et al. (4 authors)
Expert Opinion on Emerging Drugs
Published: Apr 2016
29 citations
3125 days before retraction
Practical Approaches to the Management of Dual Refractory Multiple Myeloma
Hans C. Lee, Tomer M. Mark, Jatin J. Shah
Current Hematologic Malignancy Reports
Published: Feb 2016
6 citations
3165 days before retraction
Paper citing SAR650984 directly induces multiple myeloma cell d...
Unknown Authors
Unknown Journal
Published: Feb 2016
3176 days before retraction
Monoclonal antibodies targeting <scp>CD</scp>38 in hematological malignancies and beyond
Niels W.C.J. van de Donk, Maarten L. Janmaat, Tuna Mutis et al. (8 authors)
Immunological Reviews Open Access
Published: Feb 2016
306 citations
3177 days before retraction
Vision Statement for Multiple Myeloma: Future Directions
Kenneth C. Anderson
Cancer treatment and research
Published: Jan 2016
4 citations
3217 days before retraction
Lysosomal membrane permeabilization in cell death: new evidence and implications for health and disease
Ana Serrano‐Puebla, Patricia Boya
Annals of the New York Academy of Sciences
Published: Nov 2015
173 citations
3255 days before retraction